Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma

Published:2011-06 Issue:6 Volume:35 Page:787-792
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Kita Aya,Nakahara Takahito,Yamanaka Kentaro,Nakano Kenji,Nakata Mari,Mori Masamichi,Kaneko Naoki,Koutoku Hiroshi,Izumisawa Nobuyuki,Sasamata Masao

Funder

Astellas Pharma, Inc., Japan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference34 articles.

1. Treatment of non-Hodgkin's lymphoma;Armitage;N Engl J Med,1993

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

4. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte;Feugier;J Clin Oncol,2005

5. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antitumor Effects and the Potential Mechanism of 10-HDA against SU-DHL-2 Cells;Pharmaceuticals;2024-08-20

2. A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death;Journal of the American Chemical Society;2023-04-05

3. Survivin Small Molecules Inhibitors: Recent Advances and Challenges;Molecules;2023-02-01

4. High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients;Cancers;2022-01-11

5. YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression;Anticancer Research;2020-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3